All In Biotech

Investigational drug · Phase 3

MWN109 1

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM).

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

4 still active

All registered trials

11

Any phase or sponsor naming "MWN109 1"

First trial start

2025

Aug 23, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MWN109 1", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Overweight , Obesity
  • Type 2 Diabetes Mellitus (T2DM)

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "MWN109 1" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Overweight , Obesity

  • EcnoglutideXW003, VRB-101Phase 38 trials

    Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea

  • MWN109 2Phase 36 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • MWN109 3Phase 35 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • zovaglutideZT002Phase 33 trials

    Beijing QL Biopharmaceutical Co.,Ltd · Obesity, Overweight , Obesity, Overweight or Obesity

  • matching dosagePhase 22 trials

    Hangzhou Sciwind Biosciences Co., Ltd. · Weight Management, Overweight , Obesity, Overweight and/or Obesity

  • MWN109 4Phase 22 trials

    Shanghai Minwei Biotechnology Co., Ltd · Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity

  • ALV-100Phase 21 trial

    Alveus Therapeutics, Inc. · Overweight , Obesity, Adults

  • SRSD384Phase 21 trial

    Sirius Therapeutics Co., Ltd. · Overweight , Obesity

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.